Oxybutynin 3.9mg/24h transdermal patch (Kentera®)

Following a full submission.

Oxybutynin transdermal patch (Kentera®) is accepted for restricted use within NHS Scotland for the treatment of urge incontinence and/or increased urinary frequency and urgency in patients with unstable bladder, restricted to patients who derive clinical benefit from oral oxybutinin but who experience intolerable anticholinergic side effects. It should be used in conjunction with non-pharmacological measures, including pelvic floor muscle exercises and bladder retraining.

Transdermal oxybutynin appears to have similar efficacy to oral antimuscarinics and a lower rate of anticholinergic adverse events. However, patients have the additional effect of application site reactions, which in some patients lead to treatment discontinuation. Transdermal oxybutynin has a lower total cost than oral tolterodine, but a higher total cost than oral oxybutynin.